Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05540665 · ClinicalTrials.gov registry record · Phase 2
Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT05540665 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 19 participants.
The verdict
NCT05540665, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).
Interventions
- DRUG Placebo (Normal Saline)
- DRUG Daxdilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-04-26 |
| Est. Completion | 2024-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05540665
The ClinicalTrials.gov registry entry for NCT05540665 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (Normal Saline) is the first listed.
NCT05540665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05540665 about?
NCT05540665 is a clinical study titled "Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)". Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).
What is the current status of trial NCT05540665?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2023-04-26. Estimated completion is 2024-01-04.
What interventions are being tested in trial NCT05540665?
The interventions under investigation include: Placebo (Normal Saline) (DRUG), Daxdilimab (DRUG).
Who is sponsoring clinical trial NCT05540665?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.